Matrix decomposition in meta‐analysis for extraction of adverse event pattern and patient‐level safety profile.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 806, doi. 10.1002/pst.2109
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2021 AND VI 20 AND IP 4
Results: 16
1
2
Search for relevant subsets of binary predictors in high dimensional regression for discovering the lead molecule.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 898, doi. 10.1002/pst.2117
- By:
- Publication type:
- Article
3
Progression‐free survival in oncological clinical studies: Assessment time bias and methods for its correction.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 864, doi. 10.1002/pst.2115
- By:
- Publication type:
- Article
4
Logistic retainment interval dose exploration design for Phase I clinical trials of cytotoxic agents.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 850, doi. 10.1002/pst.2114
- By:
- Publication type:
- Article
5
Using recurrent time‐to‐event models with multinomial outcomes to generate toxicity profiles.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 840, doi. 10.1002/pst.2113
- By:
- Publication type:
- Article
6
Power and sample size for GEE analysis of incomplete paired outcomes in 2 × 2 crossover trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 820, doi. 10.1002/pst.2112
- By:
- Publication type:
- Article
7
A simulation‐free group sequential design with max‐combo tests in the presence of non‐proportional hazards.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 879, doi. 10.1002/pst.2116
- By:
- Publication type:
- Article
8
Estimands in hematologic oncology trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 793, doi. 10.1002/pst.2108
- By:
- Publication type:
- Article
9
How to choose a time zero for patients in external control arms.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 783, doi. 10.1002/pst.2107
- By:
- Publication type:
- Article
10
A comparison of reweighting estimators of average treatment effects in real world populations.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 765, doi. 10.1002/pst.2106
- By:
- Publication type:
- Article
11
On kernel machine learning for propensity score estimation under complex confounding structures.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 752, doi. 10.1002/pst.2105
- By:
- Publication type:
- Article
12
Principal stratum strategy: Potential role in drug development.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 737, doi. 10.1002/pst.2104
- By:
- Publication type:
- Article
13
Statistical considerations in clinical trial design with event‐free survival as the primary efficacy endpoint.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 721, doi. 10.1002/pst.2103
- By:
- Publication type:
- Article
14
Optimising the trade‐off between type I and II error rates in the Bayesian context.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 710, doi. 10.1002/pst.2102
- By:
- Publication type:
- Article
15
A robust permutation test for the concordance correlation coefficient.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 696, doi. 10.1002/pst.2101
- By:
- Publication type:
- Article
16
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 4, p. 693, doi. 10.1002/pst.2036
- Publication type:
- Article